Opendata, web and dolomites
  1. home
  2. trasparenza
  3. open h2020
  4. proskit

PROSKit SIGNED

Prostate cancer urinary diagnostic kit based on RNA biomarkers

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0

 PROSKit project word cloud

Explore the words cloud of the PROSKit project. It provides you a very rough idea of what is the project "PROSKit" about.

validate    stabilise    stabilization    accurate    sensitivity    assay    price    biotechnology    28    tested    10    proskit    reduce    clinical    minutes    offers    intact    positive    gt    inexpensive    proposing    certify    patients    surgery    unnecessary    collected    11    laboratory    blood    protocol    collect    device    patented    samples    biopsy    rna    unstable    billion    stability    rapid    point    collection    analysed    diagnostic    ready    patient    specialized    mix    care    urine    market    lt    home    false    license    location    cancer    biopsies    60    psa    proprietary    simultaneously    hours    kits    business    central    platform    invasively    acids    tools    competitors    biomarkers    days    14    amplifiable    2025    respect    85    revenues    lab    pca3    segment    core    nucleic    molecular    informative    environment    tests    holdings    requiring    thousands    dna    validation    sampling    extend    validated    perform    arcis    preserving    capability    weeks    room    throughput    preparation    anywhere    diagnosis    discriminative    biomarker    specificity    temperature    chemicals    prostate    poc   

Project "PROSKit" data sheet

The following table provides information about the project.

Coordinator		 ARCIS BIOTECHNOLOGY HOLDINGS LIMITED 

Organization address
address: SUITE F42, THE INNOVATION CENTRE KECKWICK LANE
city: DARESBURY WARRINGTON
postcode: WA4 4FS
website: n.a.

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.
 Coordinator Country United Kingdom [UK]
 Total cost 71˙429 €
 EC max contribution 50˙000 € (70%)
 Programme 1. H2020-EU.3. (PRIORITY 'Societal challenges)
2. H2020-EU.2.3. (INDUSTRIAL LEADERSHIP - Innovation In SMEs)
3. H2020-EU.2.1. (INDUSTRIAL LEADERSHIP - Leadership in enabling and industrial technologies)
 Code Call H2020-SMEInst-2018-2020-1
 Funding Scheme SME-1
 Starting year 2020
 Duration (year-month-day) from 2020-01-01   to  2020-06-30

 Partnership

Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    ARCIS BIOTECHNOLOGY HOLDINGS LIMITED UK (DARESBURY WARRINGTON) coordinator 50˙000.00

Map

 Project objective

Arcis Biotechnology Holdings developed and patented PROSKit, a molecular diagnostic platform for the diagnosis of prostate cancer based on urine analysis, able to reduce the number of false positive from the PSA test and so the number of unnecessary biopsies. PROSKit is a proprietary mix of chemicals, that can stabilise nucleic acids (RNA/DNA) in urine for up to 2 weeks at room temperature and then allow sampling at home or Point of Care (PoC) using a patient-friendly sample collection technology, preserving unstable RNA biomarkers and analysis in specialized clinical environment through the PCA3 biomarker. With respect to current diagnostic methods (PSA biopsy), PROSKit offers i) Rapid- samples ready for analysis in <3 minutes, results in <2 hours if tested at surgery, compared to days for biopsy, ii) Accurate- greater sensitivity and specificity than current PSA blood test: PCA3 presents a 28% higher discriminative capability than PSA; iii) Inexpensive- as informative as multi-core biopsy for <10% of the price; iv) High throughput- PROSKit samples can be collected anywhere, non-invasively and thousands analysed simultaneously at a central location. Compared to competitors proposing RNA stabilization requiring laboratory analyses, complex procedures and specific tools, PROSKit offers stabilization at room temperature and with no lab equipment in 3 minutes. Intact amplifiable RNA biomarkers have already been validated for 7 days stability but needs to extend validation for >14 days, validate the protocol for patients to collect urine and analysts to perform assay; certify design of PROSKit device and cost for the device and define agreement with partners for distribution and license for execution of tests. DNA/RNA Sample preparation business market revenues are expected to reach 1.85 billion € in 2025. Kits segment represents 60% of the market: 1.11 billion € in 2025.

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "PROSKIT" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "PROSKIT" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.3.;H2020-EU.2.3.;H2020-EU.2.1.)

Colourganisms (2020)

Microbial production of custom-made, pure and sustainable anthocyanins

Read More  

VINOQUANT11SUPERPLUS (2019)

A digital based system for measuring, showing and regulation of the complexe system of wine feremtation with high precision via a Bluetooth -Refractometer, a Software and a Bluetooth Thermostat

Read More  

TAPPXSSAI (2019)

Development of a system for automatic ad insertion into on-demand streaming video to provide new monetization mechanisms to the media industry

Read More